Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Richard Kefford(Broad Institute), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Hassane M. Zarour(University of Pittsburgh), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amita Patnaik(South Texas Accelerated Research Therapeutics), Antoni Ribas(University of California, Los Angeles), Marisa Dolled‐Filhart(Fox Chase Cancer Center), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Caroline Robert(Institut Gustave Roussy), Tara C. Gangadhar(University of Pennsylvania), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 91
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k